CurrentUnitedHealthcarePolicy 1 = 2025 P 1135-13

Syprine (trientine hydrochloride) prior authorization

Defines prior authorization and reauthorization criteria for Syprine (trientine hydrochloride) for treatment of Wilson's disease, and affects providers requesting pharmacy benefit coverage under UnitedHealthcare plans.

Policy Summary

PayerUnitedHealthcare

PolicySyprine (trientine hydrochloride) prior authorization

Policy CodePolicy 1 = 2025 P 1135-13

Change TypeNo material changes

Effective DateSep 1, 2025

Next Review Date

Key ActionRequest initial prior authorization with documentation of Wilson's disease diagnosis and history of intolerance, failure, or contraindication to penicillamine.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsinitial authorization duration

12 monthsreauthorization duration

6/2022–6/2025recent P&T review dates

Program 2025 P 1135-13policy identifier

Coverage Criteria for Syprine (trientine hydrochloride)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Initial Therapy — Covered when ALL of the following are met

Covered when ALL of the following are met

Initial Authorization for Syprine or trientine hydrochloride: Diagnosis of Wilson's disease (hepatolenticular degeneration).

Authorization will be issued for 12 months

Initial Authorization for Syprine or trientine hydrochloride: History of intolerance, failure, or contraindication to penicillamine.

Authorization will be issued for 12 months

Brand Syprine (trientine hydrochloride) is noted in the policy as typically excluded from coverage for most plans; however, coverage can vary by plan. Providers must check member-specific benefit plans and any applicable state mandates or federal requirements to determine whether the brand product is excluded for a given member. (See policy history noting that the brand is typically excluded for most plans.)

When a plan excludes the brand, consideration of generic trientine hydrochloride may be appropriate if the member’s benefit allows it and the authorization criteria are otherwise satisfied.

Use of Syprine may be denied when the member’s specific benefit plan excludes the brand or when state mandates or federal regulatory requirements restrict coverage. The policy explicitly states that coverage can be impacted by member-specific benefit plan coverage and state mandates.

Prior authorization decisions may also rely on other utilization management programs or policies; if the member’s plan excludes Syprine or does not provide pharmacy benefit coverage for the medication, the request may be denied regardless of clinical indications.

Provider Actions and Documentation Requirements

Prior Authorization

Initial Authorization

Initial prior authorization requires a diagnosis of Wilson's disease (hepatolenticular degeneration) and a history of intolerance, failure, or contraindication to penicillamine. Authorization will be issued for 12 months.

Diagnosis: Wilson's disease (hepatolenticular degeneration)
Requirement: History of intolerance, failure, or contraindication to penicillamine
Approval period: 12 months

Note

Position vs penicillamine

Syprine (trientine hydrochloride) and trientine hydrochloride are indicated for patients intolerant of penicillamine and are not interchangeable with penicillamine. Use should be reserved for patients for whom continued treatment with penicillamine is not possible due to intolerable or life‑threatening adverse effects.

Syprine and trientine hydrochloride are alternatives when penicillamine is not tolerated
Not interchangeable with penicillamine; reserved for intolerance or contraindication

Documentation Required

Required documentation

Documentation of positive clinical response is required for reauthorization. Prior authorization may also be approved based on previous claim/medication history, relevant ICD‑10 diagnosis codes, and/or automated claim logic per UnitedHealthcare program rules. Authorizations for reauthorization are issued for 12 months.

Reauthorization criterion: Documentation of positive clinical response to therapy
Reauthorization approval period: 12 months
UnitedHealthcare may approve based on prior claims/medication history and diagnosis codes where applicable
Supply limits may apply

Denial Risk

Denial risk due to plan exclusions or mandates

Coverage may be affected by state mandates, federal regulatory requirements, and the member's specific benefit plan. Syprine (trientine hydrochloride) is often excluded under some plans; tried/failed or other criteria may apply. Verify member benefit coverage and any plan‑specific exclusions or utilization management programs before prescribing.

Coverage may vary by state mandate and federal/regulatory requirements
Member-specific benefit plan coverage can exclude Syprine (trientine hydrochloride)
Check plan specifics for tried/failed requirements and other utilization management rules

Clinical and Product Background

Syprine (trientine hydrochloride) is indicated for treatment of patients with Wilson's disease (hepatolenticular degeneration) who are intolerant of penicillamine. It is reserved for situations in which continued treatment with penicillamine is not possible because of intolerable or life‑threatening adverse effects. Syprine and penicillamine are not interchangeable; authorization for Syprine requires documentation that penicillamine is not tolerated, has failed, or is contraindicated.

Step	Requirement
1	Patient must have intolerance, failure, or contraindication to penicillamine prior to approval

Quantity Limits and Supply

Syprine / trientine hydrochloride — Supply limits may be in place

Quantity limit policySupply limits may be in place for Syprine / trientine hydrochloride

Approval sourcesUnitedHealthcare may approve initial and reauthorization based on previous claims/medication history, diagnosis codes (ICD-10), and/or claim logic

Program variabilityUse of automated approval and re‑approval processes varies by program and/or therapeutic class

Reauthorization alignmentSupply limits and approval processes align with program-specific reauthorization periods